Search Results - "Rosa, Potyra R"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
  2. 2

    Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month Results by Lam, Byron L., Davis, Janet L., Gregori, Ninel Z., MacLaren, Robert E., Girach, Aniz, Verriotto, Jennifer D., Rodriguez, Belen, Rosa, Potyra R., Zhang, Xiaojun, Feuer, William J.

    Published in American journal of ophthalmology (01-01-2019)
    “…To report the final results of a phase 2 high-dose gene therapy clinical trial in choroideremia. Design: Phase 2 clinical trial. Participants: Six men (aged…”
    Get full text
    Journal Article
  3. 3

    Differentiating Mild Papilledema and Buried Optic Nerve Head Drusen Using Spectral Domain Optical Coherence Tomography by Kulkarni, Kaushal M., MD, Pasol, Joshua, MD, Rosa, Potyra R., MD, Lam, Byron L., MD

    Published in Ophthalmology (Rochester, Minn.) (01-04-2014)
    “…Purpose To evaluate the clinical utility of spectral domain optical coherence tomography (SD-OCT) in differentiating mild papilledema from buried optic nerve…”
    Get full text
    Journal Article
  4. 4

    Characteristics and Surgical Outcomes of Comitant Esotropia in an Adult Population Between 18 and 60 Years Old by Cavuoto, Kara M., Tibi, Charlotte, Rosa, Potyra R., Capo, Hilda

    Published in American journal of ophthalmology (01-11-2024)
    “…To describe the clinical characteristics and surgical outcomes of adults with comitant nonaccommodative esotropia. Retrospective case series. Retrospective…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial by Lam, Byron L, Feuer, William J, Schiffman, Joyce C, Porciatti, Vittorio, Vandenbroucke, Ruth, Rosa, Potyra R, Gregori, Giovanni, Guy, John

    Published in JAMA ophthalmology (01-04-2014)
    “…IMPORTANCE Establishing the natural history of G11778A Leber hereditary optic neuropathy (LHON) is important to determine the optimal end points to assess the…”
    Get more information
    Journal Article
  7. 7

    Retinal ganglion cell dysfunction in asymptomatic G11778A: Leber hereditary optic neuropathy by Guy, John, Feuer, William J, Porciatti, Vittorio, Schiffman, Joyce, Abukhalil, Fawzi, Vandenbroucke, Ruth, Rosa, Potyra R, Lam, Byron L

    “…To report the serial evaluation of asymptomatic eyes of subjects with mutated G11778A mitochondrial DNA. Forty-five asymptomatic G11778A Leber hereditary optic…”
    Get full text
    Journal Article
  8. 8

    Relationship Between Optic Nerve Protrusion Measured by OCT and MRI and Papilledema Severity by Chang, Yu-Cherng C, Alperin, Noam, Bagci, Ahmet M, Lee, Sang H, Rosa, Potyra R, Giovanni, Gregori, Lam, Byron L

    “…To develop measures of optic nerve protrusion length (NPL) from optical coherence tomography (OCT) and magnetic resonance imagining (MRI) and compare these…”
    Get full text
    Journal Article
  9. 9

    Analysis of Socioeconomic Factors Affecting Follow-Up in a Glaucoma Screening Program by Staropoli, Patrick C, Lee, Richard K, Kroger, Zachary A, Somohano, Karina, Feldman, Matthew, Verriotto, Jennifer D, Aldahan, Adam, Rosa, Potyra R, Feuer, William J, Zheng, D Diane, Lee, David J, Lam, Byron L

    Published in Clinical ophthalmology (Auckland, N.Z.) (01-01-2021)
    “…To determine what socioeconomic factors affect follow-up in a glaucoma screening program. This was a retrospective cohort study of six health fairs in South…”
    Get full text
    Journal Article
  10. 10

    Macular Retinal Sublayer Thicknesses in G11778A Leber Hereditary Optic Neuropathy by Lam, Byron L, Burke, Samuel P, Wang, Mindy X, Nadayil, Gloria A, Rosa, Potyra R, Gregori, Giovanni, Feuer, William J, Cuprill-Nilson, Sophia, Vandenbroucke, Ruth, Zhang, Xiaojun, Guy, John

    “…To determine macular retinal sublayer thickness changes in G11778A Leber hereditary optic neuropathy (LHON). The authors performed a cross-sectional study by…”
    Get more information
    Journal Article
  11. 11

    Ventriculoperitoneal Shunt as a Treatment of Visual Loss in Idiopathic Intracranial Hypertension by Huang, Laura C, Winter, Timothy W, Herro, Angela M, Rosa, Potyra R, Schiffman, Joyce C, Pasol, Joshua, Trombly, Ryan S, Tawfik, Mike, Lam, Byron L

    Published in Journal of neuro-ophthalmology (01-09-2014)
    “…BACKGROUND:The aims of this study were to evaluate visual function outcomes in idiopathic intracranial hypertension (IIH) patients who underwent…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With RPGR Gene Variations by von Krusenstiern, Lenore, Liu, Jiajun, Liao, Eileen, Gow, James A, Chen, Guo, Ong, Tuyen, Lotery, Andrew J, Jalil, Assad, Lam, Byron L, MacLaren, Robert E

    Published in JAMA ophthalmology (01-03-2023)
    “…X-linked retinitis pigmentosa (XLRP) is a severe cause of early-onset RP in male individuals, characterized by degeneration of photoreceptors, an extinguished…”
    Get more information
    Journal Article
  14. 14

    Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial results by Digre, Kathleen B, Bruce, Beau B, McDermott, Michael P, Galetta, Kristin M, Balcer, Laura J, Wall, Michael

    Published in Neurology (16-06-2015)
    “…OBJECTIVE:The study purpose was to examine vision-specific and overall health-related quality of life (QOL) at baseline in Idiopathic Intracranial Hypertension…”
    Get full text
    Journal Article
  15. 15

    Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension by Wall, Michael, Falardeau, Julie, Fletcher, William A, Granadier, Robert J, Lam, Byron L, Longmuir, Reid A, Patel, Anil D, Bruce, Beau B, He, Hua, McDermott, Michael P

    Published in Neurology (01-09-2015)
    “…OBJECTIVES:Determine potential risk factors for progressive visual field loss in the Idiopathic Intracranial Hypertension Treatment Trial, a randomized…”
    Get full text
    Journal Article
  16. 16